<SEC-DOCUMENT>0001193125-21-104082.txt : 20210401
<SEC-HEADER>0001193125-21-104082.hdr.sgml : 20210401
<ACCEPTANCE-DATETIME>20210401164258
ACCESSION NUMBER:		0001193125-21-104082
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20210331
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210401
DATE AS OF CHANGE:		20210401

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DELCATH SYSTEMS, INC.
		CENTRAL INDEX KEY:			0000872912
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				061245881
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-16133
		FILM NUMBER:		21798679

	BUSINESS ADDRESS:	
		STREET 1:		1633 BROADWAY
		STREET 2:		SUITE 22C
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019
		BUSINESS PHONE:		(212) 489-2100

	MAIL ADDRESS:	
		STREET 1:		1633 BROADWAY
		STREET 2:		SUITE 22C
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DELCATH SYSTEMS INC
		DATE OF NAME CHANGE:	19990607
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d22722d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dcth="http://www.delcath.com/20210331" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body>
 <div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric id="Hidden_dei_SecurityExchangeName" name="dei:SecurityExchangeName" contextRef="duration_2021-03-31_to_2021-03-31">NASDAQ</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityAddressStateOrProvince" name="dei:EntityAddressStateOrProvince" contextRef="duration_2021-03-31_to_2021-03-31">NY</ix:nonNumeric> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2021-03-31_to_2021-03-31">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2021-03-31_to_2021-03-31">0000872912</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="dcth-20210331.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2021-03-31_to_2021-03-31"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000872912</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-03-31</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, DC 20549</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <ix:nonNumeric name="dei:DocumentType" contextRef="duration_2021-03-31_to_2021-03-31">8-K</ix:nonNumeric></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section 13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2021-03-31_to_2021-03-31" format="ixt:datemonthdayyearen">March 31, 2021</ix:nonNumeric></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2021-03-31_to_2021-03-31">DELCATH SYSTEMS, INC.</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact Name of Registrant as Specified in Its Charter)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2021-03-31_to_2021-03-31" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2021-03-31_to_2021-03-31">001-16133</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2021-03-31_to_2021-03-31">06-1245881</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(State or other jurisdiction of<br />incorporation or organization)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Commission<br />File Number)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(IRS Employer<br />Identification No.)</span></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2021-03-31_to_2021-03-31">1633 Broadway</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2021-03-31_to_2021-03-31">Suite 22C</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2021-03-31_to_2021-03-31">New York</ix:nonNumeric>, <span style=" -sec-ix-hidden:Hidden_dei_EntityAddressStateOrProvince">New York</span> <span style="font-size:1pt">,</span> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2021-03-31_to_2021-03-31">10019</ix:nonNumeric></span></td></tr></table> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Address of principal executive offices) (Zip Code)</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2021-03-31_to_2021-03-31">(212)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2021-03-31_to_2021-03-31">489-2100</ix:nonNumeric></span></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Registrant&#8217;s telephone number, including area code)</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not Applicable</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former name or former address, if changed since last report)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2021-03-31_to_2021-03-31" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2021-03-31_to_2021-03-31" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2021-03-31_to_2021-03-31" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2021-03-31_to_2021-03-31" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Securities registered pursuant to Section 12(b) of the Act:</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br />symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange<br />on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2021-03-31_to_2021-03-31">Common Stock, $.01 par value</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2021-03-31_to_2021-03-31">DCTH</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"> <span style=" -sec-ix-hidden:Hidden_dei_SecurityExchangeName">The NASDAQ Capital Market</span> </span></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR &#167;240.12b-2).</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2021-03-31_to_2021-03-31" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;2.02.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Results of Operations and Financial Condition. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&#160;31, 2021, Delcath Systems, Inc. (the &#8220;Company&#8221;) issued a press release, furnished as Exhibit 99.1 and incorporated in this Item 2.02 by reference, announcing its financial results for the fiscal quarter and fiscal year ended December&#160;31, 2020. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information contained in this Item 2.02, including Exhibit 99.1, is being furnished, and shall not be deemed filed for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of Section&#160;18. Furthermore, the information contained in this Item 2.02, including Exhibit 99.1, shall not be incorporated by reference into any registration statement filed by the Company under the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated therein by reference. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;8.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Other Events. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&#160;31, 2021, the Company issued a press release announcing&#160;positive preliminary results from its Phase 3 FOCUS Trial of HEPZATO in patients with metastatic ocular melanoma. On the same date, the Company issued an additional press release announcing additional information regarding the power calculation for the Phase 3 FOCUS Trial. The full text of these press releases are attached as Exhibits 99.2 and 99.3, respectively, and incorporated in this Item 8.01 by reference. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;9.01.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:7%"></td>
<td style="width:90%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"><span style="font-weight:bold">Exhibit&#160;No.</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Description</span></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d22722dex991.htm">Press Release of the Company, dated March&#160;31, 2021, announcing financial results for the fiscal quarter and fiscal year ended December&#160;31, 2020 </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d22722dex992.htm">Press Release of the Company, dated March&#160;31, 2021, announcing positive preliminary results from its Phase 3 FOCUS Trial </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.3</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d22722dex993.htm">Press Release of the Company, dated March&#160;31, 2021, announcing additional information regarding FOCUS Trial power calculation </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive File (the cover page tags are embedded within the Inline XBRL document)</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURE </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:45%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:3%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:5%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:44%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="5" style="vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">DELCATH SYSTEMS, INC.</p></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Date: April&#160;1, 2021</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="3" style="vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Gerard Michel</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Name:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Gerard Michel</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Chief Executive Officer</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d22722dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="margin-top:0pt;margin-bottom:0pt; margin-right:39%">


<IMG SRC="g22722g0401231535808.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Delcath Systems, Inc. Announces Fourth Quarter 2020 Results, Highlights Preliminary Positive FOCUS Trial Results;
Conference Call Today at 8:00am Eastern Time </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March&nbsp;31, 2021 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NEW YORK, March&nbsp;31, 2021 (GLOBE NEWSWIRE) &#151; Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of
primary and metastatic cancers of the liver, today reported business highlights and financial results for the fourth quarter ended December&nbsp;31, 2020, and earlier today reported preliminary topline data. The company will host its quarterly call
at 8:00am ET today, with a primary focus on discussing the preliminary top line data. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><B>Recent Business Highlights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><I>During and since the fourth quarter of 2020, the company: </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Reported positive preliminary results from the FOCUS Clinical Trial (NCT02678572) for Patients with Hepatic
Dominant Ocular Melanoma treated with HEPZATO based on an analysis of currently evaluable patients. The preliminary analysis included 87% of treated patients and final results are expected later in the year. The primary endpoint, overall response
rate (ORR), as determined by an independent review committee, exceeded the prespecified threshold for success. Additionally, both prespecified ORR and Progression Free Survival comparative analyses against the best alternative care arm demonstrated
a statistically significant improvement. The safety profile was consistent with the safety profile of CHEMOSAT treatment described in previous European single-center and multi-center publications with no new safety signals observed in this patient
population. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Initiated a consulting engagement to select a portfolio of <FONT STYLE="white-space:nowrap">follow-on</FONT>
indications which will maximize the value of the HEPZATO Kit and CHEMOSAT platform. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Completed an underwritten public offering of common stock at a price of $13.25 per share yielding
$22.2&nbsp;million in gross proceeds. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Strengthened the executive team with the appointment of Gerard Michel as Chief Executive Officer and Kevin Muir
as Vice President of Commercial Operations. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;The fourth quarter marked the start of a critical transformation for Delcath,&#148;
said Gerard Michel, CEO of Delcath. &#147;Since October, we have attracted new investors, strengthened the management team and, most importantly, released preliminary results from the FOCUS trial which, as of this compilation, suggests a significant
improvement in the benefit risk ratio versus an earlier generation of Delcath&#146;s proprietary percutaneous hepatic perfusion system. We look forward to continued progress in 2021, as we prepare both to file an NDA in early 2022 and expand the
development of HEPZATO into additional areas of high unmet need.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Fourth Quarter 2020 Financial Results: </B><I> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I></I></B><I>Income Statement Highlights.</I><B><I> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Product revenue for the three months ended December&nbsp;31, 2020 was approximately $379&nbsp;thousand, compared to $398&nbsp;thousand for the prior year
period from our sales of CHEMOSAT procedures in Europe. Selling, general and administrative expenses were approximately $4.5&nbsp;million compared to $2.1&nbsp;million in the prior year quarter. Research and development expenses for the quarter were
$2.7&nbsp;million compared to $2.7&nbsp;million in the prior year quarter. Total operating expenses for the quarter were $7.3&nbsp;million compared with $4.8&nbsp;million in the prior year quarter. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We recorded a net loss for the three months ended December&nbsp;31, 2020, of $7.0&nbsp;million, compared to a net income of $12.5&nbsp;million for the same
period in 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Balance Sheet Highlights. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At
December&nbsp;31, 2020, we had cash, cash equivalents and restricted cash totaling $28.8&nbsp;million, as compared to cash, cash equivalents and restricted cash totaling $10.2&nbsp;million at December&nbsp;31, 2019. During the three months ended
December&nbsp;31, 2020 and December&nbsp;31, 2019, we used $4.6&nbsp;million and $5.4&nbsp;million, respectively, of cash in our operating activities. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Conference Call Information </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: March&nbsp;31, 2021 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Time: 8:00 AM Eastern Time </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Toll Free: <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">877-407-8035</FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">International: <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">201-689-8035</FONT></FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The call will also be available over the Internet and accessible at:<B> <U>https://www.webcaster4.com/Webcast/Page/2475/40544</U> </B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Delcath Systems, Inc.</B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Delcath Systems, Inc. is an
interventional oncology company focused on the treatment of primary and metastatic liver cancers. Our investigational product &#150; HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system) &#150; is designed to administer
high-dose chemotherapy to the liver while minimizing systemic exposure and associated side effects. In addition to the FOCUS Trial which is investigating the treatment of mOM, we have initiated a global Phase 3 clinical trial for intrahepatic
cholangiocarcinoma (ICC) called the ALIGN Trial. We have paused our work on the ALIGN Trial while we reevaluate the trial design. HEPZATO KIT has not been approved by the U.S. Food&nbsp;&amp; Drug Administration (FDA) for sale in the U.S. In Europe,
our system is marketed under the trade name Delcath CHEMOSAT<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Hepatic Delivery System for Melphalan (CHEMOSAT) and has been CE Marked and used at major medical centers to treat a wide range of
cancers of the liver. CHEMOSAT is being marketed under an exclusive licensing agreement with medac GmbH, a privately held multi-national pharmaceutical company headquartered in Germany that specializes in the treatment and diagnosis of oncological,
urological and autoimmune diseases. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Safe Harbor / Forward-Looking Statements</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news
release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to,
uncertainties relating to: the timing and results of the Company&#146;s clinical trials, including without limitation the mOM and ICC clinical trial programs, as well as the receipt of additional data and the performance of additional analyses with
respect to the mOM clinical trial, our determination whether to continue the ICC clinical trial program or to focus on other alternative indications, and timely monitoring and treatment of patients in the global Phase 3 mOM clinical trial and the
impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on the completion of our clinical trials; the impact of the presentations at major medical conferences and future clinical results consistent with the data presented; approval
of Individual Funding Requests for reimbursement of the CHEMOSAT procedure; the impact, if any, of ZE reimbursement on potential CHEMOSAT product use and sales in Germany; clinical adoption, use and resulting sales, if any, for the CHEMOSAT system
to deliver and filter melphalan in Europe including the key markets of Germany and the UK; the Company&#146;s ability to successfully commercialize the HEPZATO KIT/CHEMOSAT system and the potential of the HEPZATO KIT/CHEMOSAT system as a treatment
for patients with primary and metastatic disease in the liver; our ability to obtain reimbursement for the CHEMOSAT system in various markets; approval of the current or future HEPZATO KIT/CHEMOSAT system for delivery and filtration of melphalan or
other chemotherapeutic agents for various indications in the U.S. and/or in foreign markets; actions by the FDA or foreign regulatory agencies; the Company&#146;s ability to successfully enter into strategic partnership and distribution arrangements
in foreign markets and the timing and revenue, if any, of the same; uncertainties relating to the timing and results of research and development projects; and uncertainties regarding the Company&#146;s ability to obtain financial and other resources
for any research, development, clinical trials and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these
forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact:</B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Delcath Investor Relations</I> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email: <U>investorrelations@delcath.com</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Hayden IR</I>
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">James Carbonara </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">(646)-755-7412</FONT></FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U><B>james@haydenir.com</B> </U></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DELCATH SYSTEMS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consolidated Balance Sheet </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(in thousands, except share and per share data)</I> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>December&nbsp;31,</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>December&nbsp;31,</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,575</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,002</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivables, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Inventories</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">855</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">654</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,670</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,759</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32,338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,617</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property, plant and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,351</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">735</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT>
assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">946</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">860</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34,635</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities and Stockholders&#146; Equity (Deficit) </B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B></B>Current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,774</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,533</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,947</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue, current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">525</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">482</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease liabilities, current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">664</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible notes payable, current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,368</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,035</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,994</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue, <FONT STYLE="white-space:nowrap">non-current</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,072</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease liabilities, <FONT STYLE="white-space:nowrap">non-current</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible notes payable, <FONT STYLE="white-space:nowrap">non-current</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,557</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,569</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and contingencies (Note 13)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; Equity (Deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock, $.01 par value; 10,000,000 shares authorized; 20,631 and 41,517 shares issued and
outstanding at December&nbsp;31, 2020 and December&nbsp;31, 2019, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $.01 par value; 40,000,000 and 1,000,000,000 shares authorized; 5,996,101 and 67,091
shares issued and outstanding at December&nbsp;31, 2020 and December&nbsp;31, 2019, respectively*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">417,449</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">364,785</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(395,327</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(371,171</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive (loss) income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(104</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,078</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,357</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities and stockholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34,635</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">reflects, a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-seven</FONT></FONT>
hundred (1:700) reverse stock split effected on December&nbsp;24, 2019. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DELCATH SYSTEMS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consolidated Statements of Operations and Comprehensive Loss </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(in thousands, except share and per share data) </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Product revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">490</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">479</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of goods sold</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(640</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(719</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross profit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,006</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">861</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,490</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,309</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,769</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(21,303</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(19,908</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of the warrant liability, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,832</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,493</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on issuance of financial instrument</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,720</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(175</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,746</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(24,156</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8,879</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deemed dividend for triggering of warrant down round feature</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(55</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(24,211</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8,879</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(24,156</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8,879</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other comprehensive (loss) income:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign currency translation adjustments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(132</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(22</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(24,288</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8,901</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common share data:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic loss per common share*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8.35</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(342.83</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted loss per common share*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8.35</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(342.83</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average number of basic shares outstanding*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,897,827</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average number of diluted shares outstanding*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,897,827</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">reflects, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-seven</FONT></FONT> hundred
(1:700) reverse stock split effected on December&nbsp;24, 2019. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g22722g0401231535933.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Source: Delcath Systems, Inc. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>d22722dex992.htm
<DESCRIPTION>EX-99.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.2 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt; margin-right:39%">


<IMG SRC="g22722g0401231535808.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Delcath Systems, Inc. Announces Positive Preliminary Results from Phase 3 FOCUS Trial of HEPZATO in Patients with
Metastatic Ocular Melanoma </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March&nbsp;31, 2021 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Based on Preliminary Data, FOCUS Trial Achieves Prespecified Success Threshold </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Conference Call Today at 8:00am Eastern Time </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NEW YORK, March&nbsp;31, 2021 (GLOBE NEWSWIRE) &#151; Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of
primary and metastatic cancers of the liver, today announced positive <FONT STYLE="white-space:nowrap">top-line</FONT> preliminary results from the company&#146;s Phase 3 FOCUS trial of HEPZATO KIT (melphalan hydrochloride for injection/hepatic
delivery system) in patients with liver dominant metastatic ocular melanoma (mOM). </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Based on the preliminary analysis of 87% of enrolled patients using prespecified analyses the Independent Review
Committee (IRC) assessed Overall Response Rate (ORR) of 29.2% [95% Confidence Interval (CI): 20.1, 39.8] in the Intent to Treat (ITT) population which exceeded the predefined success criteria (21.0%) for the primary ORR endpoint.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Based on predefined exploratory analyses, evaluable patients in the HEPZATO arm had a statistically significant
improvement over Best Alternative Care (BAC) in the following prespecified endpoints: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ORR of 32.9% [95% CI: 22.8, 44.4] versus 13.8% [95% CI: 3.9, 31.7] for the BAC arm
<FONT STYLE="white-space:nowrap">(Chi-square</FONT> P&lt;0.05). </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Median Progression Free Survival of 9.0 months [95% CI: 6.2,11.8] versus 3.1 months [95% CI: 2.7, 5.7] for the
BAC arm (HR=0.41; p&lt;0.001). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Disease Control Rate of 70.9% [95% CI: 59.6, 80.6] versus 37.9% [95% CI: 20.7, 57.7] for patients in the
BAC arm (p&lt;0.002). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Duration of Response and Overall Survival are not yet evaluable. Since not all patients were evaluable for all time points, these
preliminary analyses may change as data matures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The safety profile in this trial was consistent with the safety profile of PHP treatment described in
European single-center and multi-center publications with no new safety signals observed in this patient population. In the HEPZATO safety population of 94 patients, 38 patients (40.4%) experienced a treatment-emergent serious adverse event. The
most commonly reported treatment-emergent serious adverse events were thrombocytopenia (14.9% of patients), neutropenia (10.6% of patients), and leukopenia (4.2% of patients), which were well-manageable. 5% of patients experienced treatment-emergent
serious cardiac adverse events. In all cases the events resolved with no ongoing complications. There were no treatment-related deaths in the trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Metastatic ocular melanoma is a disease with a dismal prognosis and new therapies are urgently needed,&#148; noted Dr.&nbsp;Jonathan Zager MD FACS, lead
investigator of the FOCUS study, senior member and Director of Regional Therapies at Moffitt Cancer Center. &#147;The strength of these preliminary efficacy data, including progression free survival and overall response rates, coupled with an
improved safety profile versus the first-generation product, suggests that HEPZATO would offer a compelling clinical benefit were it approved by FDA.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;While the analysis is preliminary and the trial is still ongoing, these results strongly suggest that the final FOCUS dataset will demonstrate a
significantly improved benefit-risk profile compared with BAC that could form the basis of our NDA resubmission to the FDA,&#148; said Gerard Michel, CEO of Delcath. &#147;We look forward to reporting additional results later in the year as the data
matures.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About the FOCUS Trial and the Preliminary Analysis </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These preliminary results are based on a data cut on March&nbsp;12, 2021 and include 79 treated HEPZATO patients for whom there are at least 2 imaging
timepoints from which to evaluate response or were censored after the first scan due to progression or death. 11 additional patients were treated but are not yet evaluable in the HEPZATO arm. Another 11 patients were enrolled in the HEPZATO arm and
not treated. 29 of 32 treated BAC patients were available for analysis. 10 patients were enrolled in the BAC arm and not treated. Data are expected to continue to evolve as additional patients and time points become evaluable. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FOCUS trial is intended to evaluate the efficacy of HEPZATO treatment for patients with mOM with the
primary endpoint of ORR as assessed by an IRC per RECIST v1.1. Per protocol, patients were to be treated every 6 weeks to 8 weeks until the earlier of 6 cycles or progression. Tumor responses were to be assessed every 12 weeks (+/- 2 weeks) until
progression. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The single arm trial was powered to demonstrate a superior ORR versus checkpoint inhibitors, one of the few mOM treatment categories with a
significant amount of peer reviewed publications. The checkpoint inhibitor ORR was calculated based on a meta-analysis covering 16 different publications and 476 patients. Based on those assumptions a 21.0% ORR was required to demonstrate
superiority over the checkpoint inhibitors at a 95% confidence interval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The single arm trial was initially designed and conducted as a randomized
controlled study with a BAC comparator arm before being amended to a single arm trial. While the modified trial was not powered to test superiority versus BAC, comparative analyses against the BAC arm were included in the revised statistical
analysis plan </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conference Call Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Jonathan Zager MD FACS, lead investigator of the FOCUS study, senior member and Director of Regional Therapies at Moffitt Cancer Center will join the
Delcath management team during today&#146;s conference call. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: March&nbsp;31, 2021 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Time: 8:00 AM Eastern Time </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Toll Free: <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">877-407-8035</FONT></FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">International: <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">201-689-8035</FONT></FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The call will also be available over the Internet and accessible at:<B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>https://www.webcaster4.com/Webcast/Page/2475/40544</U> About HEPZATOTM KIT and CHEMOSAT<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The HEPZATOTM KIT (melphalan hydrochloride for injection/hepatic delivery system), or HEPZAT O TM , is a drug/device combination product HEPZATO is
designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. In Europe, our commercial product is a stand-alone medical device and is approved for sale under the trade name CHEMOSAT<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has been used at major medical centers to treat a wide range of cancers of the liver. In the United States, HEPZATO is considered a
combination drug and device product regulated by the United States Food and Drug Administration, or the FDA. Primary jurisdiction for regulation of HEPZATO has been assigned to the FDA&#146;s Center for Drug Evaluation and Research. The FDA has
granted Delcath six orphan drug designations (five for melphalan in ocular melanoma, cutaneous melanoma, cholangiocarcinoma, hepatocellular carcinoma, and neuroendocrine tumor indications and one for doxorubicin in the hepatocellular carcinoma
indication). HEPZATO has not been approved for sale in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In Europe, CHEMOSAT is regulated as a Class&nbsp;IIb medical device and
received its CE Mark in 2012. We are commercializing CHEMOSAT in select markets in the United Kingdom and the European Union, or EU, where we believe the prospect of securing reimbursement coverage for the use of CHEMOSAT is strongest. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Metastatic Ocular Melanoma </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Approximately <FONT
STYLE="white-space:nowrap">5,000-6,200</FONT> cases of ocular melanoma are diagnosed in the United States and Europe annually, and approximately 50% of these patients will develop metastatic disease. Of metastatic cases of ocular melanoma,
approximately 90% of patients develop liver involvement. According to Lane et al., <I>JAMA Ophthalmol</I>. 2018 Sep <FONT STYLE="white-space:nowrap">1;136(9):981-98,</FONT> once ocular melanoma has spread to the liver, median overall survival for
these patients is generally 3.9 months (untreated) to 6.3 months (treated). There is no one standard of care for patients with ocular melanoma liver metastases. Based on 2018 research, an estimated <FONT STYLE="white-space:nowrap">2,500-3,100</FONT>
patients with ocular melanoma liver metastases in the United States, the United Kingdom and the EU may be eligible for treatment with HEPZATO annually. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Delcath Systems, Inc. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Delcath Systems, Inc. is an
interventional oncology company focused on the treatment of primary and metastatic liver cancers. Our investigational product &#150; HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system) &#150; is designed to administer
high-dose chemotherapy to the liver while minimizing systemic exposure and associated side effects. In addition to the FOCUS Trial which is investigating the treatment of mOM, we have initiated a global Phase 3 clinical trial for intrahepatic
cholangiocarcinoma (ICC) called the ALIGN Trial. We have paused our work on the ALIGN Trial while we reevaluate the trial design. HEPZATO KIT has not been approved by the U.S. Food&nbsp;&amp; Drug Administration (FDA) for sale in the U.S. In Europe,
our system is marketed under the trade name Delcath CHEMOSAT<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Hepatic Delivery System for Melphalan (CHEMOSAT) and has been CE Marked and used at major medical centers to treat a wide range of
cancers of the liver. CHEMOSAT is being marketed under an exclusive licensing agreement with medac GmbH, a privately held multi-national pharmaceutical company headquartered in Germany that specializes in the treatment and diagnosis of oncological,
urological and autoimmune diseases. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Safe Harbor / Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news
release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to,
uncertainties relating to: the timing and results of the Company&#146;s clinical trials, including without limitation the mOM and ICC clinical trial programs, as well as the receipt of additional data and the performance of additional analyses with
respect to the mOM clinical trial, our determination whether to continue the ICC clinical trial program or to focus on other alternative indications, and timely monitoring and treatment of patients in the global Phase 3 mOM clinical trial and the
impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on the completion of our clinical trials; the impact of the presentations at major medical conferences and future clinical results consistent with the data presented; approval
of Individual Funding Requests for reimbursement of the CHEMOSAT procedure; the impact, if any, of ZE reimbursement on potential CHEMOSAT product use and sales in Germany; clinical adoption, use and resulting sales, if any, for the CHEMOSAT system
to deliver and filter melphalan in Europe including the key markets of Germany and the UK; the Company&#146;s ability to successfully commercialize the HEPZATO KIT/CHEMOSAT system and the potential of the HEPZATO KIT/CHEMOSAT system as a treatment
for patients with primary and metastatic disease in the liver; our ability to obtain reimbursement for the CHEMOSAT system in various markets; approval of the current or future HEPZATO KIT/CHEMOSAT system for delivery and filtration of melphalan or
other chemotherapeutic agents for various indications in the U.S. and/or in foreign markets; actions by the FDA or foreign regulatory agencies; the Company&#146;s ability to successfully enter into strategic partnership and distribution arrangements
in foreign markets and the timing and revenue, if any, of the same; uncertainties relating to the timing and results of research and development projects; and uncertainties regarding the Company&#146;s ability to obtain financial and other resources
for any research, development, clinical trials and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these
forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Delcath Investor Relations </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email: <U>investorrelations@delcath.com</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Hayden IR
</I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">James Carbonara</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(646)-755-7412</FONT></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><U>james@haydenir.com </U></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g22722g0401231535933.jpg" ALT="LOGO">
</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Source: Delcath Systems, Inc. </P> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.3
<SEQUENCE>4
<FILENAME>d22722dex993.htm
<DESCRIPTION>EX-99.3
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.3 </B></P> <P STYLE="margin-top:0pt;margin-bottom:0pt; margin-right:39%">


<IMG SRC="g22722g0401231535808.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Delcath Systems, Inc. Shares Additional Information Regarding FOCUS Trial Power Calculation </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March&nbsp;31, 2021 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>20.1% Lower Bound of
Preliminary ORR Analysis Exceeds Required 8.3% Threshold </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NEW YORK, March&nbsp;31, 2021 (GLOBE NEWSWIRE) &#151; Delcath Systems, Inc. (NASDAQ: DCTH),
an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today provided additional information regarding the power calculation for the Phase 3 FOCUS trial of HEPZATO KIT (melphalan hydrochloride for
injection/hepatic delivery system) in patients with liver dominant metastatic ocular melanoma (mOM). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the summer of 2018, the Company amended the
protocol for the FOCUS trial to a single arm design. In consultation with FDA, the FOCUS single arm trial was powered to demonstrate a superior Overall Response Rate (ORR) versus checkpoint inhibitors, one of the few mOM treatment categories with a
significant amount of peer reviewed publications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A point estimate of 21.0% ORR was calculated as the requirement to demonstrate superiority over the
checkpoint inhibitors given the planned trial size and this threshold was shared with investors. The checkpoint inhibitor ORR was calculated based on a meta-analysis covering 16 different </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">publications and 476 patients. The pooled overall response rate was 5.5% with a 95% Confidence Interval of 3.6%&#151;8.3%. To achieve statistical significance
at a 95% Confidence Interval the lower bound of the ORR for HEPZATO needs to exceed the 8.3% upper bound of the meta-analysis. A preliminary analysis of 87% of enrolled patients analyses by the Independent Review Committee yielded an ORR of 29.2%
[95% CI: 20.1, 39.8] in the Intent to Treat population, which substantially exceeds the 21.0%-point-estimate requirement. For further clarity, since the 20.1% lower bound exceeds the 8.3% upper bound of the meta-analysis the predefined success
threshold was met. Further detail is available on the events and presentations section of the company website. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Delcath Systems, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. Our investigational product
&#150; HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system) &#150; is designed to administer high-dose chemotherapy to the liver while minimizing systemic exposure and associated side effects. In addition to the FOCUS Trial
which is investigating the treatment of mOM, we have initiated a global Phase 3 clinical trial for intrahepatic cholangiocarcinoma (ICC) called the ALIGN Trial. We have paused our work on the ALIGN Trial while we reevaluate the trial design. HEPZATO
KIT has not been approved by the U.S. Food&nbsp;&amp; Drug Administration (FDA) for sale in the U.S. In Europe, our system is marketed under the trade name Delcath CHEMOSAT<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Hepatic Delivery
System for Melphalan (CHEMOSAT) and has been CE Marked and used at major medical centers to treat a wide range of cancers of the liver. CHEMOSAT is being marketed under an exclusive licensing agreement with medac GmbH, a privately held
multi-national pharmaceutical company headquartered in Germany that specializes in the treatment and diagnosis of oncological, urological and autoimmune diseases. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Safe Harbor / Forward-Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Private
Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can
cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to: the timing and results of the Company&#146;s clinical trials, including without
limitation the mOM and ICC clinical trial programs, as well as the receipt of additional data and the performance of additional analyses with respect to the mOM clinical trial, our determination whether to continue the ICC clinical trial program or
to focus on other alternative indications, and timely monitoring and treatment of patients in the global Phase 3 mOM clinical trial and the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on the completion of our clinical
trials; the impact of the presentations at major medical conferences and future clinical results consistent with the data presented; approval of Individual Funding Requests for reimbursement of the CHEMOSAT procedure; the impact, if any, of ZE
reimbursement on potential CHEMOSAT product use and sales in Germany; clinical adoption, use and resulting sales, if any, for the CHEMOSAT system to deliver and filter melphalan in Europe including the key markets of Germany and the UK; the
Company&#146;s ability to successfully commercialize the HEPZATO KIT/CHEMOSAT system and the potential of the HEPZATO KIT/CHEMOSAT system as a treatment for patients with primary and metastatic disease in the liver; our ability to obtain
reimbursement for the CHEMOSAT system in various markets; approval of the current or future HEPZATO KIT/CHEMOSAT system for delivery and filtration of melphalan or other chemotherapeutic agents for various indications in the U.S. and/or in foreign
markets; actions by the FDA or foreign regulatory agencies; the Company&#146;s ability to successfully enter into strategic partnership and distribution arrangements in foreign markets and the timing and revenue, if any, of the same; uncertainties
relating to the timing and results of research and development projects; and uncertainties regarding the Company&#146;s ability to obtain financial and other resources for any research, development, clinical trials and commercialization activities.
These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We
undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Delcath Investor Relations </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email:
<U>investorrelations@delcath.com</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Hayden IR </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">James Carbonara</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(646)-755-7412</FONT></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><U>james@haydenir.com </U></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g22722g0401231535933.jpg" ALT="LOGO">
</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Source: Delcath Systems, Inc. </P> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>dcth-20210331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2020-7 Build:20201110.1 -->
<!-- Creation date: 4/2/2021 12:35:48 AM Eastern Time -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2019-01-31"
  xmlns:dcth="http://www.delcath.com/20210331"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.delcath.com/20210331"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2019-01-31" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2011-01-31" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dcth-20210331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dcth-20210331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.delcath.com//20210331/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>dcth-20210331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2020-7 Build:20201110.1 -->
<!-- Creation date: 4/2/2021 12:35:48 AM Eastern Time -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>dcth-20210331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2020-7 Build:20201110.1 -->
<!-- Creation date: 4/2/2021 12:35:48 AM Eastern Time -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.delcath.com//20210331/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="dcth-20210331.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.delcath.com//20210331/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="24.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g22722g0401231535808.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g22722g0401231535808.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  Y =,# 2(  A$! Q$!_\0
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M.UU"PBM<2'RY2^_Y"0>BD=O6O.Z "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** /H+]FB(>5XCE(.0UN ?^_F:K
M6>IZH/C3/%:W$QSJ\L9C#':4\Q@01TQBLKX1?$G0/!.AWEMJ?VDS3RA@(TR
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M^-OBMX/N+36O#UOH;F3RY+:.<6R "7!&0.H ;O6IX"L-7MO!VF1V/@VRA<0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MU>_&J:S>Z@(1"+F=Y?*!R$W$G&?;-4J* "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "EW-MV[CM!R!GC-)10 4444 %%%% !1110
M4444 %%%% !6]X;\9^(/"4KOHFI26V_[Z;5=&_X"P(SQUZU@T4 =%XB\=>)O
M%85=9U:6XC7I&%6-.W55 !Z#KFN=HHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
0B@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g22722g0401231535933.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g22722g0401231535933.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  Q )8# 2(  A$! Q$!_\0
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(4AA1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>d22722d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="dcth-20210331.xsd" xlink:type="simple"/>
    <context id="duration_2021-03-31_to_2021-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872912</identifier>
        </entity>
        <period>
            <startDate>2021-03-31</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <dei:SecurityExchangeName
      contextRef="duration_2021-03-31_to_2021-03-31"
      id="Hidden_dei_SecurityExchangeName">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityAddressStateOrProvince
      contextRef="duration_2021-03-31_to_2021-03-31"
      id="Hidden_dei_EntityAddressStateOrProvince">NY</dei:EntityAddressStateOrProvince>
    <dei:AmendmentFlag contextRef="duration_2021-03-31_to_2021-03-31">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2021-03-31_to_2021-03-31"
      id="Hidden_dei_EntityCentralIndexKey">0000872912</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2021-03-31_to_2021-03-31">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2021-03-31_to_2021-03-31">2021-03-31</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2021-03-31_to_2021-03-31">DELCATH SYSTEMS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2021-03-31_to_2021-03-31">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2021-03-31_to_2021-03-31">001-16133</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2021-03-31_to_2021-03-31">06-1245881</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2021-03-31_to_2021-03-31">1633 Broadway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2021-03-31_to_2021-03-31">Suite 22C</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2021-03-31_to_2021-03-31">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="duration_2021-03-31_to_2021-03-31">10019</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2021-03-31_to_2021-03-31">(212)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2021-03-31_to_2021-03-31">489-2100</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2021-03-31_to_2021-03-31">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2021-03-31_to_2021-03-31">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2021-03-31_to_2021-03-31">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2021-03-31_to_2021-03-31">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2021-03-31_to_2021-03-31">Common Stock, $.01 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2021-03-31_to_2021-03-31">DCTH</dei:TradingSymbol>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2021-03-31_to_2021-03-31">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140157772696040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000872912<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">DELCATH SYSTEMS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-16133<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">06-1245881<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1633 Broadway<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 22C<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10019<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(212)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">489-2100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, $.01 par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">DCTH<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>12
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( %N%@5('04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " !;A8%22ZR(#N\    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M3L,P#(9?!>7>NNG*#E&7"XC3)B$Q"<0M2KPMHFFBQ*C=V].&K1."!^ 8^\_G
MSY);'83V$9^C#QC)8KH;7=<GH<.&G8B" $CZA$ZE<DKT4_/@HU,T/>,1@M(?
MZHA05]4:')(RBA3,P"(L1"9;HX6.J,C'"][H!1\^8Y=A1@-VZ+"G!+SDP.0\
M,9S'KH4;8(811I>^"V@68J[^B<T=8)?DF.R2&H:A'%8Y-^W X6VW?<GK%K9/
MI'J-TZ]D!9T#;MAU\NOJX7'_Q&1=U;RHFJ+B>[X632WNF_?9]8??3=AY8P_V
M'QM?!64+O^Y"?@%02P,$%     @ 6X6!4IE<G",0!@  G"<  !,   !X;"]T
M:&5M92]T:&5M93$N>&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M
M3A^%$5B-;'EDD81_OT<V$,N6#>V23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R
M>&#9+]O6N[<OWN!7,B0103 9IZ_PP JE3%ZU6FD PSA]R1,2P]R"BPA+>!3+
MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,!
M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K
MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2
MBW <!.!1NY["G?1LOZ1!";2C:=!DV/;:KI&FJHU33]/W?=_KFVB<"HU;3]-K
M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M J<11S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$%     @ 6X6!4I>*NQS
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M"Q4&L&]R( DNR94;4EWI>::W=Y-[2:AU[D&P]_ :C1W-CQ^W_ %02P,$%
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MO-9.&G_FB^$_7G\!4$L! A0#%     @ 6X6!4@=!36*!    L0   !
M         ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " !;A8%2
M2ZR(#N\    K @  $0              @ &O    9&]C4')O<',O8V]R92YX
M;6Q02P$"% ,4    " !;A8%2F5R<(Q &  "<)P  $P              @ '-
M 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( %N%@5+4J9.*100
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M2P$"% ,4    " !;A8%2)!Z;HJT   #X 0  &@              @ &Z$0
M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " !;A8%299!Y
MDAD!  #/ P  $P              @ &?$@  6T-O;G1E;G1?5'EP97-=+GAM
7;%!+!08     "0 ) #X"  #I$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>95</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d22722d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.delcath.com//20210331/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="d22722d8k.htm">d22722d8k.htm</File>
    <File>d22722dex991.htm</File>
    <File>d22722dex992.htm</File>
    <File>d22722dex993.htm</File>
    <File>dcth-20210331.xsd</File>
    <File>dcth-20210331_lab.xml</File>
    <File>dcth-20210331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>18
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d22722d8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "d22722d8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "dcth-20210331_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "dcth-20210331_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "dcth-20210331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd",
      "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2019-01-31": 4,
    "total": 4
   },
   "keyCustom": 0,
   "keyStandard": 95,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "dcth",
   "nsuri": "http://www.delcath.com/20210331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d22722d8k.htm",
      "contextRef": "duration_2021-03-31_to_2021-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.delcath.com//20210331/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d22722d8k.htm",
      "contextRef": "duration_2021-03-31_to_2021-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.delcath.com//20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.delcath.com//20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.delcath.com//20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.delcath.com//20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.delcath.com//20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.delcath.com//20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.delcath.com//20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.delcath.com//20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.delcath.com//20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.delcath.com//20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.delcath.com//20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.delcath.com//20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.delcath.com//20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.delcath.com//20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.delcath.com//20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.delcath.com//20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.delcath.com//20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.delcath.com//20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.delcath.com//20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.delcath.com//20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.delcath.com//20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.delcath.com//20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.delcath.com//20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>19
<FILENAME>0001193125-21-104082-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-21-104082-xbrl.zip
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M=Q1,NPA%4$\]]D08BJ'^IB<DD)Y\8P5CHH3'7?*FK']R%S^\L8[+IV>E8-5
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M[>J.0<CL6@[\:(&U"',._6BP,B>DK^D[Z]NJ4M:63:Z\1UG9P&()'B31PM5
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MA'W>IP&;U?[>*_I+Q8D.0[(EIWYY&L13>JWTJ^8];$H+#F-?S17^@%I>J]M
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M?F34X9V\3ZGI?'QV+6Z&O\-HMM;<DCP,</B/ _Y?/5MW&6[_]/WH]/K_XJ0
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M5;RRZ178IM?_HI8 Y68!]QF0YT-ZW/GSZ9 $F^DG8D>"SW2$O1!:/%-4HAC
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M@ T  / E   0    9#(R-S(R9&5X.3DS+FAT;<U:;6\:21+^CL1_:+'R*I8
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MRXF8COX %SBL%2+Y;73[EU/^IR8^CP:SR_-::W]_9_-2KS_\,!M._A]?5=,
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M<4"5R\W#O1<=93SX@HO\2Z__ E!+ P04    " !;A8%2V@A:TV(#   C#
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M;0PL#)^-(_]ZQ=T._";I-,$=V*F\<+ Y^EY,$,+EW9I>AW7">?"=%X.7XU<
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M0ILI<'0RR4=43K]:K\>1H0LI9+:,K"2ZD<DL V'<9TNDM\(PL^R(D519WI&
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M,C)D97@Y.3$N:'1M4$L! A0#%     @ 6X6!4O]EH"^&%P  +%$  !
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H:"TR,#(Q,#,S,5]P<F4N>&UL4$L%!@     '  < N@$  )M@      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
